The Prescrire Awards for 2010
The 2010 Prescrire Awards: chosen in all independence by Prescrire's Editorial staff
A look back at new drugs and new indications in 2010
Prescrire's ratings of new products and indications over the last 10 years
| Prescrire's ratings of new products and indications over the last 10 years (a) |
PRESCRIRE'S RATING
|
2001 |
2002 |
2003 |
2004 |
2005 |
2006 |
2007 |
2008 |
2009 |
2010 |
| Bravo |
0 |
0 |
0 |
0 |
0 |
1 |
1 |
0 |
0 |
0 |
| A real advance |
2 |
4 |
4 |
0 |
1 |
1 |
2 |
0 |
0 |
1 (c) |
| Offers an advantage |
11 |
9 |
5 |
6 |
4 |
8 |
14 |
6 |
3 (c) |
3 (d) |
| Possibly helpful |
17 |
18 |
23 |
12 |
20 |
31 |
27 |
25 |
14 |
22 |
Nothing new
|
36 |
35 |
34 |
41 |
38 |
69 |
79 |
57 |
62 |
49 |
Not acceptable
|
9 |
6 (b) |
7 (b) |
7 |
19 (d) |
17 |
15 |
23 |
19 (d) |
19 (e) |
Judgement reserved
|
7 |
0 |
6 |
4 |
2 |
8 |
3 |
9 |
6 (e) |
3 (f) |
| Total |
82 |
72 |
79 |
4 |
84 |
135 |
141 |
120 |
104 |
97 |
| |
| Notes : |
| a - For reasons of space, this table only shows the results for the last 10 years. The previous years’ results (1981 to 2000) can be found in Prescrire Int n°58. This table shows new products (other than generics copies) and new indications proposed by drug companies to physicians and pharmacists, for use in hospitals and/or the community; and, from 2005 onwards, line extensions (new dose strengths, new form/presentations of existing drugs) and products for self-medication, rated in our French edition la revue Prescrire. A given product is counted several times if it was rated differently in its different indications. |
| b - Including two jointly marketed products. |
| c - Imatinib reassessed in inoperable or metastatic gastrointestinal stromal tumours (Prescrire Int n°114). |
d - The drugs were:
- azacitidine in some forms of poor-prognosis myelodysplasia (Prescrire Int n°113);
- canakinumab in periodic syndrome in combination with cryopyrine (Rev Prescrire n°324);
- Japanese encephalitis vaccine (Prescrire Int n°106).
|
e - The drugs were:
- fixed-dose combination of amlodipine + valsartan + hydrochlorothiazide in hypertension (Prescrire Int n°114);
- bevacizumab in metastatic breast cancer (Rev Prescrire n°317);
- capsaicin patches for neuropathic pain (Prescrire Int n°108);
- atumaxomab in malignant ascites (Prescrire Int n° 109);
- cetuximab in colon cancer (Rev Prescrire n°324);
- duloxetine in prevention of recurrent depression (Prescrire Int n°111);
- histamine in acute myeloblastic leukaemia (Rev Prescrire n°321);
- ivabradine in stable angina (Prescrire Int n°111);
- long-acting injectable olanzapine in schizophrenia (Prescrire Int n°107);
- omalizumab in severe persistent asthma in children (Prescrire Int n°115);
- omalizumab in severe persistent asthma, a reassessment (Prescrire Int n°115);
- maraviroc in first-line treatment of HIV-infected patients (Prescrire Int n°110);
- mifamurtide in osteosarcoma (Prescrire Int n°115);
- pazopanib in kidney cancer (Prescrire Int n°114);
- sildenafil (Prescrire Int n°109) and tadalafil (Rev Prescrire n°321) in stage II (mild) pulmonary hypertension;
- temsirolimus in mantle cell lymphoma (Prescrire Int n°111);
- trabectedin in ovarian cancer (Prescrire Int n°115);
- vinflunine in bladder cancer after failure of first-line cisplatin-based treatment (Prescrire Int n ° 112).
|
f - The drugs were:
- autologous chondrocytes in autologous chondrocyte grafting for knee cartilage damage (Prescrire Int n°116, coming in May 2011);
- imatinib as an adjuvant to surgical excision of gastrointestinal stromal tumours (Prescrire Int n ° 113);
- sapropterin in tetrahydrobiopterin deficiency (Prescrire Int n°107).
|
| ©Prescrire April 2011 |
| "New drugs and indications in 2010: inadequate assessment; patients at risk" Prescrire Int 2011: 20 (115): 105-110. (Pdf, free) |
